All In Biotech

Drug Trial Radar · NCT07445906

A Study of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment

A Phase I Clinical Study to Evaluate the Safety, Tolerability, PK and PD of RG002C0106 Injection in Adult Participants With Normal Renal Function and Mild-to-Moderate Renal Impairment

Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Mar 15, 2026

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Sponsor type
Industry
First posted
Mar 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase I trial designed to evaluate the impact of renal impairment on the efficacy and safety of the drug by comparing pharmacokinetic (PK) parameters and pharmacodynamic (PD) markers after a single subcutaneous injection of RG002C0106 between trial participants with normal renal function and those with mild to moderate renal impairment.

Conditions

  • Renal Impairments
  • IgA Nephropathy (IgAN)

Interventions

  • RG002C0106Drug

    Subcutaneous (SC) single dose 200mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Calculate the pharmacokinetic (PK) parameters:CmaxTime frame: From enrollment to the end of treatment at 4 days
  2. Calculate the pharmacokinetic (PK) parameters:TmaxTime frame: From enrollment to the end of treatment at 4 days
  3. Calculate the pharmacokinetic (PK) parameters:AUC0-12h , AUC0-24h , AUC0-t, AUC0-∞Time frame: From enrollment to the end of treatment at 4 days
  4. Calculate the pharmacokinetic (PK) parameters:t½Time frame: From enrollment to the end of treatment at 4 days
  5. Calculate the pharmacokinetic (PK) parameters:Vd/FTime frame: From enrollment to the end of treatment at 4 days
  6. Incidence of adverse events (AEs) and serious adverse events (SAEs) related to the investigational drug.Time frame: up to 169 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • No. 50 in Huatuo Road, Daxing District

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.